WASHINGTON — Alexandra Eala rallied from a set down to defeat top seed Jessica Pegula 4-6, 6-4, 6-0 in the final of the Mubadala DC Open on Monday, capturing her first career WTA Tour singles title and becoming the first player from the Philippines to win a title at the tour level.

The 21-year-old’s breakthrough capped a stunning week in Washington, where she knocked out three seeded players, including a Grand Slam champion and a reigning Olympic gold medalist, en route to the biggest win of her young career. Eala entered the tournament ranked No. 28 in the world and is now projected to climb into the top 20 for the first time ahead of the U.S. Open.

A dramatic, rain-interrupted final

The championship match spanned two days after heavy rain and lightning forced officials to suspend play Sunday night, with Pegula leading by a set and ahead in the second. Play resumed Monday at midday, and Eala wasted little time seizing control, closing out the match in one hour and 45 minutes once action got back underway.

From behind in the second set, Eala mounted a remarkable turnaround, winning the final nine games of the match outright. She capped the comeback with a dominant 6-0 third set in which she surrendered just eight points to Pegula, the world No. 3 and 2019 Washington champion who had entered the final chasing her 12th career title.

Eala was especially sharp behind her first serve throughout the match, winning 84.4% of those points (38 of 45) compared with Pegula’s 56.5%. She converted four of her nine break-point opportunities and won 79 of the 140 total points played in the match, despite not recording a single ace and committing three double faults.

Redemption after past heartbreak

Monday’s victory marked a measure of redemption for Eala, whose only previous appearance in a tour-level singles final ended in painful fashion. At last year’s Lexus Eastbourne Open, she held four championship points against Maya Joint before ultimately falling in a third-set tiebreak. This time, facing another high-pressure moment against one of the sport’s top-ranked players, Eala repeatedly met the challenge.

Speaking after lifting the trophy, Eala reflected on the emotional weight of finally breaking through. “I feel so much love. My first chance at a title,” she said, addressing the crowd on court following the win.

A run through the sport’s elite

Eala’s path to the title ran through a gauntlet of accomplished opponents. She opened her tournament by defeating 2024 Olympic champion Zheng Qinwen, then knocked out No. 7 seed and defending champion Leylah Fernandez in the second round. In the quarterfinals, she ousted No. 2 seed Elina Svitolina, before overcoming No. 3 seed and four-time Grand Slam champion Naomi Osaka in the semifinals to reach her first WTA 500-level final.

With her victories over Svitolina and Pegula, Eala’s win total against top-10 opponents this season climbed to seven, tying her with Elena Rybakina and Svitolina herself for the most top-10 victories on tour in 2026.

Pegula praises her opponent

Pegula, who had won the two players’ only previous meeting in the 2025 Miami Open semifinals, offered generous praise for Eala during the post-match trophy presentation, acknowledging both her opponent’s rapid rise and the passionate following she has built. “To see how far you’ve come over the last couple of years,” Pegula told Eala on court, reflecting on the Filipina’s emergence as one of the tour’s most closely watched young stars.

The result also evened the head-to-head series between the two players at one win apiece, following Pegula’s three-set victory over Eala in Miami last year.

A landmark moment for Philippine tennis

Eala’s triumph carries significance well beyond the tournament itself, marking the first time a player from the Philippines has won a WTA Tour-level singles title. Her rise has already drawn a passionate following, with a large and vocal contingent of Filipino fans packing center court throughout the tournament, a dynamic Pegula herself referenced when comparing the atmosphere in Washington to the raucous, heavily pro-Eala crowds she encountered during their earlier meeting in Miami.

Fritz claims the men’s title

In the tournament’s men’s final, played the same day, American Taylor Fritz claimed his 11th career ATP title, defeating 19-year-old Spanish rising star Rafael Jodar 7-6(2), 6-4. The win marked a significant step in Fritz’s return to peak form following a knee injury that had sidelined him earlier this season, with the American winning 81% of his first-serve points in a steady, serve-driven performance.

Prize money and rankings implications

The Mubadala DC Open featured a total prize purse of $1,637,982, with the singles champion earning $252,000. Beyond the financial reward, Monday’s result carries substantial ranking implications for both finalists. Pegula, despite the loss, is set to improve to No. 4 in the season-long WTA Race while remaining No. 3 in the overall PIF WTA Rankings. Eala, meanwhile, is projected to move into the world’s top 20 for the first time in her career, a milestone that would have seemed unlikely even to her at the start of the tournament.

With her first WTA title now secured and a significant ranking jump on the horizon, Eala heads into the U.S. Open Series as one of the tour’s most talked-about breakout stars of 2026. Her run through three seeded players, including a Grand Slam champion and a reigning Olympic gold medalist, has established her as a legitimate threat heading into the year’s final Grand Slam tournament, with fans and analysts alike now watching closely to see whether Washington marks the beginning of a sustained run near the top of the sport rather than a single standout week.

Lionel Messi has spent more than two decades rewriting football’s record books, and along the way, he has also become one of the highest-paid athletes in sports history. That combination of extraordinary output and extraordinary pay naturally invites a simple, if unofficial, question: how much is each of Messi’s career goals actually worth in dollar terms relative to what he’s been paid to play?

While no official body tracks or publishes such a figure, publicly reported data on Messi’s career goal totals and his career football earnings make it possible to arrive at a rough estimate, one that comes with significant caveats given how differently athlete compensation and career statistics are typically measured and reported.

The numbers behind the calculation

As of mid-2026, Messi has scored roughly 919 to 920 career goals across all competitions for FC Barcelona, Paris Saint-Germain, Inter Miami and the Argentina national team, according to tracking compiled by multiple outlets covering his career. That total includes 672 goals scored during his 17 seasons at Barcelona, 32 goals across two seasons at Paris Saint-Germain, and more than 80 goals since joining Inter Miami in 2023, along with well over 100 international goals for Argentina.

On the earnings side, Messi has earned more than $1.8 billion in career football contract compensation before taxes and agent fees, according to figures reported by Yahoo Sports, spanning his time at Barcelona, PSG and his current deal with Inter Miami. That figure reflects on-field playing contracts specifically, separate from the substantial additional income Messi earns through endorsements, sponsorships and business ventures.

Doing the math

Dividing that $1.8 billion in career contract earnings by roughly 920 career goals produces a figure of approximately $1.96 million per goal, or nearly $2 million for every goal Messi has scored across his professional career to date. That figure should be treated as a broad, illustrative estimate rather than a precise statistic, since it combines earnings across vastly different eras of Messi’s career, different currencies, and contracts that compensated him for far more than simply scoring goals, including playmaking, leadership, marketing value and simply drawing fans to stadiums and broadcasts.

A rate that has shifted dramatically over time

The per-goal value looks very different depending on which stage of Messi’s career is examined in isolation. Early in his time at Barcelona, Messi’s salary was a fraction of what it later became, meaning his goals during those seasons carried a far lower dollar value relative to pay than his goals do today. By contrast, during the peak of his Barcelona career, Messi signed a contract reportedly worth an average base salary of $168 million per year before bonuses, with total earnings, including endorsements, reaching roughly $200 million annually at that deal’s height.

His current arrangement with Inter Miami offers a clearer, more isolated example of how the calculation can shift depending on the timeframe used. Messi has scored 59 goals in 64 MLS regular-season appearances since joining the club, and at his $28.3 million in guaranteed annual compensation for the 2026 season, that works out to roughly $976,000 per MLS goal when measured against just his Inter Miami salary alone, a figure that notably excludes the additional $50 million or more he earns annually from endorsement deals with Apple, Adidas and other partners.

Salary is only part of the picture

Messi’s total annual income in 2026 is estimated at roughly $140 million, according to Forbes, a figure that blends his Inter Miami salary with sponsorship and endorsement revenue. Inter Miami co-owner Jorge Mas has said Messi’s overall compensation from the club, including commercial and revenue-sharing arrangements tied to Apple’s MLS broadcasting partnership, totals between $70 million and $80 million annually, well above his $25 million base salary alone.

Because so much of Messi’s modern earnings come from endorsements and business ventures rather than his playing contract itself, any true “earnings per goal” calculation depends heavily on which income sources are included. A calculation based solely on football salary produces a meaningfully different result than one that also factors in endorsement income, and neither fully captures the value Messi has generated for the clubs, leagues and brands associated with him throughout his career.

Net worth adds another layer of complexity

Messi’s overall net worth, estimated at $1.1 billion by Forbes and closer to $850 million by Celebrity Net Worth, reflects accumulated wealth after spending, taxes, investments and asset appreciation, rather than raw career earnings. That distinction matters for any attempt to connect his financial success directly to his on-field output, since net worth incorporates decisions and outcomes entirely unrelated to how many goals he has scored.

Why the exercise remains inherently imprecise

Ultimately, any “dollars per goal” calculation for an athlete like Messi functions more as a conversation-starting exercise than a rigorous financial metric. Professional athletes are paid for a wide range of contributions beyond goal-scoring, including assists, leadership, marketing appeal, ticket sales and broadcast value, all of which are baked into the massive contracts Messi has signed throughout his career. Goals remain the most visible and easily countable measure of his footballing output, which is likely why such comparisons continue to circulate among fans and analysts, even though they offer, at best, a rough and heavily caveated approximation of value.

What the numbers do show

Regardless of the precision limitations, the underlying figures underscore just how extraordinary Messi’s combination of production and earning power has been. Few athletes in any sport have combined a scoring record approaching 1,000 career goals with career playing contracts exceeding $1.8 billion, a pairing that has helped cement Messi’s standing not just as one of football’s greatest players, but as one of the highest-earning athletes in the history of professional sports.

Cancer cells that survive chemotherapy may release a common dietary sugar to help neighboring tumor cells break loose and spread throughout the body, according to a new study from The Wistar Institute that identifies a previously unknown pathway behind one of cancer’s deadliest processes.

The research, published in the journal Nature Aging, focused on ovarian cancer and found that fructose, a sugar widely consumed in the American diet, can act as a chemical signal released by cells that remain in the body after chemotherapy treatment. That signal appears capable of making nearby tumor cells more likely to detach and metastasize, a process responsible for the vast majority of deaths from the disease.

Cells that survive treatment keep sending signals

Nearly all ovarian cancer patients receive platinum-based chemotherapy, and the treatment typically produces a strong initial response. Despite that, the cancer returns in most patients and commonly spreads throughout the abdominal cavity, a process responsible for roughly 90% of deaths tied to the disease.

Researchers have previously suspected that cancer cells surviving chemotherapy might contribute to that recurrence by releasing a mix of signaling molecules, even after they stop actively dividing. To test that idea more directly, the Wistar-led research team designed an experiment separating surviving cancer cells from the substances those cells released into their environment.

“Some cancer cells that survive chemotherapy aren’t dividing anymore, but they’re still biologically active,” said Aidan Cole, a postdoctoral fellow in the lab of Katherine Aird at The Wistar Institute and the study’s first author. He explained that the cells continue releasing molecules that send signals to nearby cells, and the study is among the first to show that a nutrient, in this case fructose, can function as one of those signals.

When the team exposed other cancer cells only to the molecules released by chemotherapy-surviving cells, without exposing them to the surviving cells themselves, that exposure alone was enough to significantly boost the treated cells’ ability to spread. Cole said the finding marked the first time researchers had shown, in a preclinical model rather than simply in a lab dish, that it’s the released molecules rather than the surviving cells themselves that appear to drive the cancer’s spread.

Diet may play a larger role than previously understood

After identifying fructose as a key signaling molecule, researchers also tested whether high levels of dietary fructose, comparable to amounts found in sugary drinks, could encourage cancer spread even without prior chemotherapy exposure. That test suggested the sugar alone could promote spread, raising the possibility that everyday dietary habits might influence how the disease progresses over time.

That finding carries added significance given how widely fructose is consumed in the United States. High fructose corn syrup can account for roughly 8% to 20% of daily calorie intake for some people, according to the study. Unlike many cancer risk factors that patients have little control over, researchers noted that fructose intake is one variable people can potentially modify through diet, though they cautioned that no studies have yet tested whether reducing fructose consumption actually improves outcomes for patients.

How fructose may help cancer cells escape

To understand the mechanism behind fructose’s effect, researchers used several large-scale analytical techniques, including a CRISPR gene-editing screen, and found that fructose appears to lower cholesterol production inside neighboring cancer cells. Cholesterol plays an important structural role in helping cells remain attached to one another, functioning similarly to a biological adhesive. When cholesterol levels drop, those cellular bonds weaken, making it easier for cancer cells to separate from surrounding tissue and move elsewhere in the body.

A possible connection to a widely used class of drugs

The discovery that reduced cholesterol production may promote cancer spread also raised questions with potential clinical relevance, given that statins, cholesterol-lowering drugs used by an estimated 39 million people in the United States, work through a similar mechanism. In laboratory testing, statins alone were found to weaken the connections between cancer cells, making it easier for them to separate and spread, prompting researchers to begin investigating whether the drugs could interact with chemotherapy in ways not previously understood.

The research team was careful to stress that the findings should not be interpreted as a reason for patients to stop taking statins or any other prescribed medication. “We haven’t tested this effect in patients yet,” said Katherine Aird, professor and co-leader of the Molecular and Cellular Oncogenesis Program at The Wistar Institute’s Ellen and Ronald Caplan Cancer Center and the study’s senior author. She noted that the findings raise questions worth exploring further, particularly because ovarian cancer is most common in postmenopausal women, many of whom are already taking statins for cardiovascular health reasons unrelated to their cancer treatment.

Broader implications beyond ovarian cancer

Researchers involved in the study believe the fructose-driven pathway they identified may extend beyond ovarian cancer to other cancers that commonly spread within the torso, including pancreatic, colon and liver cancers. “We think other cancers that spread within the torso — pancreatic, colon, liver — could behave similarly,” Aird said, while cautioning that the team cannot yet call the effect universal across cancer types based on current evidence.

Aird and Cole have already begun planning follow-up studies aimed at determining whether the same mechanism can be reproduced in other forms of cancer, work that could help clarify how widely applicable the fructose-related pathway may be across different types of tumors.

A large, multi-institution collaboration

The study involved dozens of researchers from institutions including the University of Pittsburgh School of Medicine, the University of Pittsburgh, Temple University’s Lewis Katz School of Medicine, the H. Lee Moffitt Cancer Center, the University of Colorado Boulder and Anschutz Medical Campus, and the Ludwig Institute for Cancer Research at the University of Lausanne, alongside researchers at The Wistar Institute. The work was funded by multiple grants from the National Institutes of Health, along with support from organizations including the American Cancer Society, the Ovarian Cancer Research Alliance, the Congressionally Directed Medical Research Program, and the Chan Zuckerberg Initiative, among others.

While the findings offer a new and previously unrecognized explanation for how ovarian cancer may spread after chemotherapy, researchers emphasized that the connection between dietary fructose intake and cancer outcomes in actual patients remains untested. Determining whether reducing fructose consumption, adjusting statin use, or other interventions could meaningfully affect cancer progression in humans will require additional clinical research, a process the study’s authors say they are now working to pursue.